Replies to post #202873 on Biotech Values

[DewDiligence]

EXAS selling 8.05M shares at unspecified price:

http://finance.yahoo.com/news/exact-sciences-announces-agreement-sell-200100578.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

EXAS -14% on 3Q16 results and non-raised full-year 2016 guidance:

http://finance.yahoo.com/news/exact-sciences-completes-68-000-100000979.html

The number of tests in 3Q16 was 68K, and the guidance for full-year 2016 remains 240K tests. Inasmuch as EXAS performed ~160K tests during the first 9 months of 2016, the full-year guidance equates to ~80K tests during 4Q16.

Meanwhile, the compliance rate continues to slip—during the 12-month period from 8/1/15 to 7/31/16 it was down to 67%. (This means that 1/3 of patients who received Cologuard never sent in the materials for analysis.)